It might for that reason provide a novel drug applicant to the procedure of LPS-induced lung damage by using inhibition of migration of neutrophils within the blood to ruined lung tissue. Bortezomib can be a reversible proteasome inhibitor that was authorized by the United States Food and Drug Administration (FDA) https://frederics631ins4.wikistatement.com/user